

University IP Management Strategies to Maximize Social Impact



Equitable Licensing: Medical Research in the Public Interest
Berlin April 23 and 24, 2009

Carol Mimura, Ph.D.
Assistant Vice Chancellor for
Intellectual Property and Industry Research Alliances (IPIRA)
University of California, Berkeley

The University of California




at Berkeley



Decentralization of Licensing to Campuses began in 1990

UC Systemwide Office of Technology Transfer
Oakland, CA



And three National Laboratories:

L. Berkeley National (1988), L. Livermore (1985), Los Alamos (1988)

FY UC 2008 Tech Transfer Highlights*

- 1497 Inventions reported
- 224 US, 353 Foreign Patents issued
- 206 Utility Licenses/Options issued
- 8953 Active inventions
- 1856 Inventions with royalties or fees
- 1450 Active utility licenses/options
- >7000 Active US and Foreign patents

\$128 Million Licensing Income Plus \$42M settlement

*PATENTS only
*January 10, 2009

Significant Results of UC's IP Licensing Program

- More than 420 startup companies founded on UC technology
- Over 800 products on the market
- Top 10 revenue earning licenses (FY 2008)

Top 5 = 47.9% of all revenue

Top 25 = 75.6% of all revenue

"Home Run model" commercialization is long, risky, future licensing revenue is speculative

- | | |
|--|---------------------------------------|
| 1. Hepatitis B Vaccine (1981) | 6. Chromosome painting/FISH (1985) |
| 2. Treatment for intracranial aneurysms (1989) | 7. Biodegradable implant coils (1998) |
| 3. Interstitial cystitis therapy (1980) | 8. Dynamic Skin Cooling (1993) |
| 4. Egf Receptor Antibodies (1983) | 9. Camarosa Strawberry (1992) |
| 5. Bovine Growth Hormone (1980) | 10. Firefly luciferase (1984) |

University Mission and Social Compact

Teaching, Research, Dissemination of Information, Public service

University of California's (UC's) economic impact is huge:

- 7% of all R&D activity in CA takes place at UC campuses*
- 1.3% of the growth in CA Gross St. Product* is due to productivity gains resulting from the research activities of the University of CA
- >\$5B in federal funding (10 campuses)

As a research university we have a duty to ensure that basic research that has a practical application is **transmitted and deployed to benefit society**

*from *California's Future: It Starts Here (2004)* IBF consulting group

ACADEMIC TECHNOLOGY TRANSFER



Goal of "tech transfer" is to get things out into use for public benefit

Universities traditionally report such statistics internally and to AUTM
Gives the impression that revenue maximization is the goal

Patent licensing revenues (numbers of patent, patent licenses) are:

- small compared to total University research funding
- small compared to total Industry gift funding
- represent only one form of Industry-University engagement

Potential for mission distortion: profit center with goal of revenue maximization

Even at the expense of: public service, faculty needs, supporting scientific exchange and collaboration

With Ownership Comes Responsibility

As owners of IP we must demonstrate good IP management and use our resources for public benefit to effect lasting societal change

- ✓ Most TT occurs in traditional ways (teaching, graduates, consulting, informing)
- ✓ Good stewards of IP think of broad implications when they make University property proprietary
 - ✓ and don't impede public access to vital technologies for research, for cures (material transfer agreements)
- ✓ Faculty Service: reserve rights for research and education
- ✓ **Maximization of research IMPACT, not licensing revenue**



Principles in Action:
U.C. Berkeley's Socially Responsible Licensing Program

Since 2003 one of several IP rights management strategies in IPIRA

Traditional IP management doesn't address needs of Developing World

Strives to maximize the impact of our research, emphasis on poorest
<http://ipira.berkeley.edu>

Can bring resources to Berkeley for research
Typically agree to forgo or reduce future IP license revenue

Can include not patenting and/or selectively by geography

Faculty service (research funding vs. speculative license revenue)
Societal benefit

Diversify research funding sources: foundations



Goals of the Socially Responsible Licensing Program (SRLP)

- ✓ Ensure widespread **availability** of technology & healthcare in the developing world
- ✓ **Affordable** pricing

- ✓ Attribution
- ✓ Revenue sharing

- ✓ Reservations of rights
- ✓ Expeditious sharing of research materials

- ✓ Expeditious publication of scientific results in accessible journals
- ✓ IP management that provides commercial incentives, yet benefits the poor



SRLP Examples

Diagnostics

Therapeutics

- Anti-viral
- Anti-malarial

Vaccines

Agricultural Biotechnology

- Plant disease resistance
- Increased nutritional quality

Public Health - sanitation, water purity

Consumer Electronics and information technology



PDPs and PPPs

All examples rely on:

Product Development Partnerships (PDPs)

Public Private Partnerships (PPPs)

1) DIAGNOSTICS: Hand-held device Dengue Fever, Nicaragua

The Sustainable Sciences Institute – a nonprofit.

	Licensee	University
Goal	Commercial license Proof of principle	Make an impact Stimulate funding for SSI
	Deploy at cost in LMC	Catalyze commercialization
Challenge	Need IP (copycats) Nontraditional license terms	Enable 2nd generation improvement Preserve additional licensing opportunities
	Lack of profit from LMC	Patent expenses, fair valuation Commercial license to nonprofit
Solution	Pay patent costs only and receive free IP license in non-profit territories	Define for-profit and non-profit territory, Grant free license in non-profit
	Remuneration to SSI via royalty sharing if Berkeley receives royalties from for-profit licenses	"informed consent" Retain right to license for-profit companies in for-profit territories

2) THERAPEUTIC: Antiviral Compound from Native Plant

Collaborative research agreement – Commonwealth of Samoa

	Collaborator	University
Goal	•Facilitate research to purify and characterize antiviral	•Obtain materials and engage in research
	•Benefit from success -credit national, local -royalties, use the drug	•If successful, achieve affordability and accessibility of therapy
Challenge	•Need collaborator with resources, equipment •Nothing invented yet	•Unknown future licensee •With unknown tolerance to SRLP terms
	Solution	Facilitate access to botanical source, to local experts
Remuneration via royalty sharing		•Agree to share revenue with country, villages, indigenous experts •Agree to "exert reasonable efforts in licensing such IP for pb, mutual goal of providing therapy for free, at cost or minimal profit in the developing world"

3) Three licenses to Pharmaceutical companies

THERAPEUTIC: Anticarcinogenic Combination Therapy

Currently in Clinical trials Phase III - expedited review

THERAPEUTIC: Neurodegenerative disease, spinal injury

DIAGNOSTIC: STD

Exclusive patent licenses (and/or sublicenses) to Pharma Co's.

No extraordinary contractual clauses but:

NO patents outside of Japan, Canada, U.S., EPO, Australia

Reservation of rights
Commercial diligence
Comprehensive commercialization



4) AGRICULTURE / HUNGER: Plant disease resistance gene

Nonprofit Agbiotech company license

	Licensee	University
Goal	•Commercialize disease resistant crops •Maximize use of trait for agriculture, rather than for profit •Manage gene use to preserve efficacy (disease resistance can be lost if commons)	•Enable the development of pesticide-free crops for public benefit •Support licensee's goal of trait management for long term agricultural benefits
	•Commercialize at cost in "least developed" countries	•If successful, achieve affordability and accessibility for poor
Challenge	•Need IP license but with accommodations for charitable aims	•Fair valuation, public benefit •commercial license to nonprofit
Solution	•Bifurcated business model Profit in Developed world, reinvest profits in further research	•Grant no-cost sublicenses in "least developed countries" emphasis on Africa. Receive royalty elsewhere. •"informed consent" • Exclusive license: diligence requirements incl. mandatory sublicensing

5) AGRICULTURE / HUNGER: Biofortified Sorghum
PDP with Africa Harvest Foundation Coupled with free, nonexclusive license

	Collaborator& Licensee	University
Goal	<ul style="list-style-type: none"> •Access experts and IP to complement existing R&D •Receive commercial license consistent with Global Access Strategy 	<ul style="list-style-type: none"> •Participate in the PDP to produce and deploy improved sorghum in arid and semi-arid tropics with funding from Bill & Melinda Gates Foundation
	<ul style="list-style-type: none"> •If successful, achieve affordability and accessibility 	<ul style="list-style-type: none"> •If research is successful, achieve affordability and accessibility, avoid conflicting obligations
Challenge	<ul style="list-style-type: none"> •Needs existing collaborator IP, And future IP from PDP research FTO from all participants, universities, Pioneer, Syngenta 	<ul style="list-style-type: none"> •commercial license to nonprofit •NERF •some IP exists, additional IP will be developed with the funding under the PDP •other sponsors
Solution	Nonexclusive, royalty-free(NERF) license	<ul style="list-style-type: none"> •Define FOU, define Charitable Objective •NERF license to existing IP •“subject to legal ability to do so” a NERF to “project IP” to AHF

6) VACCINE: TB Vaccine Research For-profit biotech company
With Granting Agency “access” goals

	Collaborator	University
Goal	<ul style="list-style-type: none"> •Receive grant funding for company and university collaborator •If IP arises, receive assurance that license will be consistent with grant •Create business model to fund project 	<ul style="list-style-type: none"> •Engage in collaborative/sponsored research, receive research funding •If successful, achieve affordability and accessibility in target areas
Challenge	<ul style="list-style-type: none"> •Need collaborator with expertise, equipment •Invention not reduced to practice 	<ul style="list-style-type: none"> •avoid conflicting obligations •fair valuation
Solution	Letter of intent to license in the future	Agree in advance, that if successful, license to project IP will be royalty-free outside of JP, CA, EU“subject to legal ability” And NERF to US government if applicable

7) SANITATION: Water Purification Aquaya Institute (nonprofit)

	Collaborator	University
Goal	<ul style="list-style-type: none"> •Make clean drinking water accessible in ppor countries •Receive grant funding for company and university collaborator •At little or no cost •If IP arises, receive assurance that license will be consistent with grant •Allow international network to benefit 	<ul style="list-style-type: none"> •Engage in collaborative/sponsored research on water treatment/sanitation •receive research funding •Develop a new class of household consumer products for disinfecting water (surface-bound cationic antimicrobial compounds) •If successful, achieve affordability and accessibility in target areas
Challenge	<ul style="list-style-type: none"> •need collaborators, expertise •deploy at cost in economically disadvantaged countries (EDC) 	<ul style="list-style-type: none"> •avoid conflicting obligations •fair valuation •commercial license to nonprofit
Solution	Visiting Industrial fellow to Berkeley Receive NERF license in EDC for charitable purposes	Shall grant NERF license in EDCs Or nonassertion Sublicense to international network Retain right to license outside EDCs Informed consent

8) Electronics: Nokia – IP “Framework” Research Agreement

	Collaborator	University
Goal	<ul style="list-style-type: none"> •Sponsor research at cutting edge research university under a master agreement •Have a menu of choices of outcomes, within pre-negotiated framework (copyrights & pats) 	<ul style="list-style-type: none"> •Engage in collaborative/sponsored research in areas of mutual interest •Provide opportunities for faculty and students •If commercially relevant inventions arise, achieve affordability and accessibility for poor
Challenge	<ul style="list-style-type: none"> •Deploy at cost/low cost in economically disadvantaged countries (EDC) •Segregate markets, differential pricing in countries with middle & upper class incomes •Protect markets in developed world 	<ul style="list-style-type: none"> •avoid conflicting obligations •fair valuation, public benefit •SRLP terms in electronics industry •navigate antitrust concerns
Solution	<ul style="list-style-type: none"> •Deploy products for EDCs through charitable arm; •Ability to exercise convertible option •For-profit products as usual (currently sell for-profit products in EDCs) 	Structure “conversion” option from humanitarian to commercial SRLP terms for “humanitarian products” in EDCs (for BK IP that cannot be commercialized through a Nokia business unit) Subject to third party rights Informed consent

SRLP Summary

And several research agreements from federal and foundation sources

Advance commitment from Berkeley to grant royalty-free licenses and/or requirement to provide licensed products for free or at cost for humanitarian use

MECHANISMS IN USE:

- royalty-free license
- no patent rights outside if JP, CA, EU, Australia, US
- mandatory sublicensing to address unmet needs and/or achieve target price
- separate treatment of for-profit markets from non-profit markets
 - tiered pricing within a given country
 - define target countries for free or at-cost distribution
 - conversion option
- field of use licensing (define "humanitarian or charitable use)
- royalty sharing, attribution
- march in (diligence)
- informed consent
- nonassertion



Resources:

Socially Responsible Licensing at Berkeley


Humanitarian Use Clauses in Contracts


<http://ipira.berkeley.edu> then "Socially Responsible IP management"



PDP: Malaria Drug Development Partnership

- Malaria afflicts up to 500M per year, kills 1-3M. Tropical disease, under resourced - profit margins low.
- **Berkeley** (Jay Keasling) has patented technology that allows terpene synthesis genes to engineered in *E. coli* and yeast. Overproduce artemisinin for ACT.
- Reduce reliance on natural product (extracted from wormwood)
- Berkeley's start-up Co., **Amyris Biotechnologies, Inc.** refine and scale up
- **The Institute for One World Health (iOWH)** is the world's first nonprofit pharmaceutical company and has expertise in clinical trials, FDA regulatory approvals. Mission: cure infectious diseases in developing world
- Gates Foundation, Berkeley, iOWH, Amyris have a mutual goal of making the existing malaria drug affordable (\$2.40 per dose to ~24 cents).
- Neither Berkeley, iOWH, Amyris alone can see the project through to completion, **Bill & Melinda Gates Foundation** will fund if pricing and access goals are assured





**This model: seamless transitions to
accelerate & streamline translational research,
commercialization & economic development**

BASIC RESEARCH APPLIED RESEARCH CLINICAL/REGULATORY

- The model exemplifies “bench to bedside” translational research.
- Gates: hopes this structure will serve as a model for other Universities and calls it “An extraordinary public-private partnership that combines cutting edge science with a commitment to affordability and accessibility for those people in need.”
- William Haseltine: HGS founder: “The beginning of a new paradigm that could be transformational.”
- Tony Fauci, NIAID Director, “...Collaborations, coordination, and synergies between the private and public sectors are becoming increasingly essential.”

OUTCOME - Amyris

Amyris spun out of University (start-up Co.)

- bootstrap philanthropy (faster start w/Gates funding)

For profit company

Dual commercial plan

- nonprofit model for malaria
- for profit model for all other applications

IP license gives incentive

- reduce to practice for malaria (short term)
- make a profit for all other applications (biofuels, long term)

OUTCOME - University

University research funding from foundation

- larger amount, broader scope

Spun out a biotech company

- faculty and postdocs as founders “make a difference”
- bridge translational research gap
- economic development in the region

Achieves impact

- drug accessibility, affordability in 88 target countries

Reputational gains - gifts

SRLP doesn't harm university, compresses timelines

Demonstrates SRLP principles in action for Rx

OUTCOME - iOWH & Sanofi-Aventis

iOWH (nonprofit pharmaceutical company)

Achieves global health aims

- consistent with Gates Foundation global access goals

Demonstrates, through sublicense to **Sanofi-Aventis (for profit)**

- licensee with commercial diligence requirements doesn't itself, have to do it all
- uptake can be achieved by sublicensing a multinational pharma. (worldwide mfg, distribution) long term business model

Sanofi-Aventis

- US FDA expedited review voucher
- Navigate drug regulatory systems in dev. World
- In-country presence for long term goals
- Goodwill, reputational gains

Public & Private Cooperation, Collaboration, PPPs and PDPs Help Us to Implement a Shared Vision

Of translating basic, academic, research results into goods and services

Of accelerating innovation and catalyzing commercialization


Science-to-technology transition can be expedited through innovative Public-Private Partnerships




- ✓ input from industry provides valuable insight
- ✓ problems to be solved
- ✓ where and how academics can help



How can a university "afford" to developing world licenses?
Industry Contracts & IP Management Berkeley reorganized into IPIRA




Two Peer Divisions under Common Management



Self-perpetuating cycle that stimulates innovation

A given outcome is not at the expense of another



Berkeley's Restructured Approach in IPIRA

"New" definition of Technology Transfer

TT is an ongoing relationship continuum between the public and private sector, not a single transaction

Means transfers in both directions

IP licensing is merely one form of TT

Public-Private Partnerships (PPPs) and Product Development Partnerships (PDPs) are crucial

And a New Definition of Success in IPIRA

If success is measured only by:

- numbers of patents and patent licenses
- patent royalties & fees you bring in

THEN your licensing practices will reflect that :

- Nonremunerative transactions & free licenses less desirable
- Services will have a lower priority
- Schizophrenia (service or business?)
- Misaligned expectations



If success is defined by: *Social impact, translational efficiency, innovation acceleration global outreach, uptake, collaboration, sharing, gifts, reputational gains, affiliation, PDPs, PPPs*

Including: speed of, efficiency of, efficacy of above

Then: No single model for transacting TT is dominant.

- IP licensing becomes less important, industry-specific needs can be addressed
- Full spectrum of IP management strategies is available to deploy innovation for maximal societal impact

"Alternatives" to traditional TT are equally viable: patent pooling, public domain, open source, royalty free licensing, commons, not patenting in certain geographies

Metrics for Measuring Impact

Social impact, translational efficiency, innovation acceleration, global outreach, uptake, collaboration, sharing, gifts, reputational gains, affiliation, PDPs, PPPs
Including: speed of, efficiency of, efficacy of above

Double Bottom-Line Accounting

Financial	Social Impact
Traditional metrics: # of licenses # of patents # license revenue # start-up Equity, options	Neglected or tropical disease research funded, lives saved, medical costs reduced, software distributed under BSD, research tools shared, collaboration enabled, knowledge and expertise transferred...